Support: +91-22-61011756 /
1. Boolean Searches :

i. AND - Shows results where both terms on either side of the 'AND' operator are present. 'AND' must be in upper case. For example search term - delhi AND metro result - It will return records in which 'delhi' as well as 'metro' both are present.

ii. OR - Shows results where either term (or both terms) is present. 'OR' must be in upper case. For example search term - delhi OR metro result - It will return records in which either 'delhi' or 'metro' or both are present

2. Proximity Searches

A proximity search looks for terms that are within a specific distance from one another. For example, search term - 'delhi metro'~10 result - It will search for records where 'delhi' and 'metro' are found within 10 words of each other

3. Phrase searches

You can search phrases using double quotes. for e.g. 'delhi metro' result - It will return records where 'delhi metro' phrase is found.

Centre plans Rs 3,000 cr incentive package for API units

Friday, 20 Mar 2020
Share this on :
The Department of Pharmaceuticals (DoP) has proposed the creation of Rs 3,000 crore corpus for companies to set up fermentation or active pharmaceutical ingredients (APIs) units to boost domestic manufacturing in India.
The proposal is likely to be put before the Union Cabinet on 20 March 2020.
Under the proposal, the government will provide financial incentive to those pharma companies ready to invest Rs 500 crore in an existing or new plant.
DoP had given a presentation on the scheme to the Prime Minister Office (PMO) detailing outlines of the scheme. The department has also got an approval from the Expenditure Finance Committee (EFC) for the proposed scheme.
The government has been finding ways to encourage domestic manufacturing of APIs to counter a potential shortage of bulk drugs and intermediates. 
DoP has formulated the scheme in consultation with Niti Aayog, incorporating recommendations of the technical committee that DoP formed in February 2020 to look into the revival of fermentation industry, new technologies for manufacturing of APIs, costing of projects and identification of strategic business models.
As part of the plans to reduce dependence on China for bulk drugs or APIs, and give impetus to domestic industry, the Ministry of Environment, Forest and Climate Change (MoEF&CC) is also contemplating putting bulk drug manufacturing units in B2 category as they will not be required to submit an environment impact assessment (EIA) report. 
The move is expected to reduce significant time taken to get approvals for starting bulk drug units in India.
If the project falls in B category, it goes to state governments for clearance, which has further categorised it into B1 and B2 projects. B2 projects do not require preparation of EIA reports.
Post Your Comments


Sign up to start your free trial

Are you...


Free access to Project News and Analysis

Project and Tender Alert in your mailbox

Explore the largest Database on Projects for free

Be part of Online Projects Community

User login
Start Exploring

Subscribe to any of our premium plans to

Access to complete information on 43000+ projects

Use our Notification service for instant update on projects and tenders

Closely monitor your opportunities with "WORKSPACE"

Use our online platform for promotions of your products and services